• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:30:31 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PRVL alert in real time by email
    SC 13G/A 1 tm214737d40_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G*/
    (Rule 13d-102)    
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
    Prevail Therapeutics Inc.
    (Name of Issuer)
     
    Common stock, par value $0.0001 per share
    (Title of Class of Securities)
     

    74140Y101

    (CUSIP Number)
     

    December 31, 2020

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨     Rule 13d-1(b)
    x
        Rule 13d-1(c)
    ¨
         Rule 13d-1(d)

     

     

    */ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 2 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    2,411,014 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.0%1

     

    12.

     

    TYPE OF REPORTING PERSON

    IA; OO; HC

     

     

    1      The percentages reported in this Schedule 13G/A are based upon 34,246,433 shares of common stock outstanding as of November 9, 2020 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 13, 2020).

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 3 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors Holdings LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)      ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    2,411,014 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.0%

     

    12.

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 4 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    2,411,014 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.0%

     

    12.

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 5 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    9,916 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    Less than 0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    BD, OO

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 6 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    CALC IV LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)      ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    10,010 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    Less than 0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 7 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    10,010 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    Less than 0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 8 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Kenneth Griffin

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

     

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

     

    5.

     

     

    SOLE VOTING POWER

    0

     

    6.

     

     

    SHARED VOTING POWER

     

    2,421,024 shares

     

    7.

     

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

     

    10.

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

     

    IN; HC

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 9 of 14 Pages

     

    Item 1(a)Name of Issuer
     Prevail Therapeutics Inc.
      
    Item 1(b)Address of Issuer’s Principal Executive Offices
     430 East 29th Street, Suite 1520, New York, New York 10016
      
    Item 2(a)Name of Person Filing
    This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), CALC IV LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to shares of common stock (and options to purchase common stock) of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), Citadel Securities, and CRBU Holdings LLC, a Delaware limited liability company (“CRBH”).
      
     Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities and CRBH. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
      
     The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
      
    Item 2(b)Address of Principal Business Office
    The address of the principal business office of each of the Reporting Persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.
      
    Item 2(c)Citizenship
    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
      
    Item 2(d)Title of Class of Securities
     Common stock, par value $0.0001 per share
      
    Item 2(e)CUSIP Number
    74140Y101

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 10 of 14 Pages

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;
         
    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;
         
    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;
         
    (d)¨ Investment company registered under Section 8 of the Investment Company Act;
         
    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
         
    (j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 11 of 14 Pages

     

    Item 4 Ownership

     

    A.Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

     

    (a)Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 2,411,014 shares of common stock.

     

    (b)The number of shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes approximately 7.0% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 2,411,014

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 2,411,014

     

    B.Citadel Securities LLC

     

    (a)Citadel Securities LLC may be deemed to beneficially own 9,916 shares of common stock.

     

    (b)The number of shares that Citadel Securities LLC may be deemed to beneficially own constitutes less than 0.1% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 9,916

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 9,916

     

    C.CALC IV LP and Citadel Securities GP LLC

     

    (a)Each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own 10,010 shares of common stock.

     

    (b)The number of shares that each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes less than 0.1% of the common stock outstanding.

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 12 of 14 Pages

     

     (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 10,010

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 10,010

     

    D.Kenneth Griffin

     

    (a)Mr. Griffin may be deemed to beneficially own 2,421,024 shares of common stock.

     

    (b)The number of shares that Mr. Griffin may be deemed to beneficially own constitutes approximately 7.1% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 2,421,024

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 2,421,024

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 13 of 14 Pages

     

    Item 5Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person
     Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
     See Item 2 above

     

    Item 8Identification and Classification of Members of the Group
     Not Applicable

     

    Item 9Notice of Dissolution of Group
     Not Applicable

     

    Item 10Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 74140Y101 13G/A Page 14 of 14 Pages

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 16th day of February, 2021.

     

    CITADEL SECURITIES LLC CITADEL ADVISORS LLC

     

    By: /s/ Guy Miller  By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory    Gregory Johnson, Authorized Signatory

     

     

    CALC IV LPCITADEL ADVISORS HOLDINGS LP

     

    By: /s/ Guy Miller  By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory    Gregory Johnson, Authorized Signatory

     

     

    CITADEL SECURITIES GP LLCCITADEL GP LLC

     

    By: /s/ Guy Miller  By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory    Gregory Johnson, Authorized Signatory

     

     

      KENNETH GRIFFIN

     

      By: /s/ Gregory Johnson
        Gregory Johnson, attorney-in-fact*

     

     

    *     Gregory Johnson is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Jaws Acquisition Corp. on February 1, 2021.

     

     

     

     

    Get the next $PRVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Llc Advisors Orbimed

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:20:50 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Asa Abeliovich decreased ownership by 100% to 0 units

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:19:57 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by M Timothy Adams

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:18:50 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    SEC Filings

    View All

    SEC Form 15-12B filed

    15-12B - Prevail Therapeutics Inc. (0001714798) (Filer)

    2/1/21 6:40:58 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - Prevail Therapeutics Inc. (0001714798) (Subject)

    1/29/21 4:15:39 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Prevail Therapeutics Inc. (0001714798) (Filer)

    1/27/21 12:15:18 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly Completes Acquisition of Prevail Therapeutics

    INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. "We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and demen

    1/22/21 8:55:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly Announces Agreement to Acquire Prevail Therapeutics

    INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in

    12/15/20 6:15:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

    NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN). “Dosing the first patient in our PROCLAIM clinical trial marks an important milestone in our efforts to advance a potentially disease-modifying treatment for patients with frontotemporal dementia with GRN mutations,”

    12/11/20 7:00:00 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Financials

    Live finance-specific insights

    View All

    Lilly Completes Acquisition of Prevail Therapeutics

    INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. "We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and demen

    1/22/21 8:55:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

    NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia (FTD). PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). “The European Commission’s decision to grant orphan designation for PR006 is an important step in helping to advance this potential therapeutic optio

    11/30/20 7:00:00 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/16/21 4:39:44 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/16/21 4:30:31 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/12/21 4:19:03 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care